TIGIT's immuno-oncology teachings.
vol.25 iss.3 (2026) PD1 blockers work best when used in the morning, suggests cancer chronotherapy trial.
vol.25 iss.3 (2026) 2025's FDA approvals by regulatory designations.
vol.25 iss.3 (2026) Approvals by the China NMPA in 2025.
vol.25 iss.3 (2026) PIP4K2C: an emerging fulcrum for multiple diseases.
vol.25 iss.3 (2026) Two-step screen for CARD9 inhibitors.
vol.25 iss.3 (2026) Antibody-lectin chimeras: new checkpoint inhibitors in the toolbox.
vol.25 iss.3 (2026) Predicting small-molecule-RNA interactions.
vol.25 iss.3 (2026) Biopharma dealmaking in 2025.
(2026) 2025 FDA approvals: volume maintained, but value remains below average.
(2026) 2025 FDA approvals.
(2026) Hunting for biopharma's innovation sweet spot.
(2026) Strategies for blood-brain barrier rejuvenation and repair.
(2026) Roads and detours for CAR T cell therapy in autoimmune diseases.
(2026) Olfactory receptor activation overcomes obesity.
(2026) The Biomarkers Consortium: 20 years of advancing precision medicine.
(2026) First antibody-mimetic adnectin nabs an FDA approval.
(2026) Lilly pays US$1.2 billion for Ventyx and its oral anti-inflammatories.
(2026) Redirecting mast cells for antigen-specific cancer immunotherapy.
(2026) Kinase inhibitors trigger target degradation.
(2026) Histone methyltransferase inhibition hampers prostate cancer.
(2026) Boosting CAR T cell efficacy.
(2026) Nonopioid analgesic alleviates neuropathic pain.
(2026) Innate immune receptor agonist for cancer immunotherapy.
(2026) Prime editing to suppress nonsense mutations.
(2026) Promoting prostaglandin signalling for joint repair in osteoarthritis.
(2026) Single-dose sleeping sickness drug set for approval.
(2026) Reshaping Pfizer's drug discovery priorities.
(2026) In vivo CAR-T cells target fibrogenic cells in MASH.
(2026) Synthetic lethal strategy targets p53-deficient cancers.
(2026) FDA approves dwarfism drug.
(2026) Author Correction: Novel drug treatments for schizophrenia.
(2026) An allosteric site on cereblon.
(2026) Promoting remyelination.
(2026) Inhibiting advillin in glioblastoma.
(2026) Targeting vascular smooth muscle cells.
(2026) Gilead pays US$7.8 billion for Arcellx's next-generation CAR T candidate.
(2026) Clearing cholesterol combats secondary lymphoedema.
(2026) The pancreatic cancer drug market.
(2026) Unlocking the potential of disease prevention through regulatory science.
(2026) Accelerating the drug regulatory process through a federated cloud ecosystem.
(2026) Non-incretin approach for weight loss.
(2026) Upcoming FDA approval decisions in Q2 2026.
(2026) Digital endpoints in clinical trials: building the business case for systematic adoption.
(2026) Oral macrocyclic IL-23 inhibitor nabs FDA approval for psoriasis.
(2026) Exon skipping to treat Rett syndrome.
(2026) Enhancing CAR-NK cell efficacy in solid tumours.
(2026) Trikines rewire STAT signalling.
(2026) Targeted degradation of amyloid-β.
(2026) Wearable technologies in clinical trials for drug development: trends and emerging opportunities.
(2026)
vol.25 iss.3 (2026) PD1 blockers work best when used in the morning, suggests cancer chronotherapy trial.
vol.25 iss.3 (2026) 2025's FDA approvals by regulatory designations.
vol.25 iss.3 (2026) Approvals by the China NMPA in 2025.
vol.25 iss.3 (2026) PIP4K2C: an emerging fulcrum for multiple diseases.
vol.25 iss.3 (2026) Two-step screen for CARD9 inhibitors.
vol.25 iss.3 (2026) Antibody-lectin chimeras: new checkpoint inhibitors in the toolbox.
vol.25 iss.3 (2026) Predicting small-molecule-RNA interactions.
vol.25 iss.3 (2026) Biopharma dealmaking in 2025.
(2026) 2025 FDA approvals: volume maintained, but value remains below average.
(2026) 2025 FDA approvals.
(2026) Hunting for biopharma's innovation sweet spot.
(2026) Strategies for blood-brain barrier rejuvenation and repair.
(2026) Roads and detours for CAR T cell therapy in autoimmune diseases.
(2026) Olfactory receptor activation overcomes obesity.
(2026) The Biomarkers Consortium: 20 years of advancing precision medicine.
(2026) First antibody-mimetic adnectin nabs an FDA approval.
(2026) Lilly pays US$1.2 billion for Ventyx and its oral anti-inflammatories.
(2026) Redirecting mast cells for antigen-specific cancer immunotherapy.
(2026) Kinase inhibitors trigger target degradation.
(2026) Histone methyltransferase inhibition hampers prostate cancer.
(2026) Boosting CAR T cell efficacy.
(2026) Nonopioid analgesic alleviates neuropathic pain.
(2026) Innate immune receptor agonist for cancer immunotherapy.
(2026) Prime editing to suppress nonsense mutations.
(2026) Promoting prostaglandin signalling for joint repair in osteoarthritis.
(2026) Single-dose sleeping sickness drug set for approval.
(2026) Reshaping Pfizer's drug discovery priorities.
(2026) In vivo CAR-T cells target fibrogenic cells in MASH.
(2026) Synthetic lethal strategy targets p53-deficient cancers.
(2026) FDA approves dwarfism drug.
(2026) Author Correction: Novel drug treatments for schizophrenia.
(2026) An allosteric site on cereblon.
(2026) Promoting remyelination.
(2026) Inhibiting advillin in glioblastoma.
(2026) Targeting vascular smooth muscle cells.
(2026) Gilead pays US$7.8 billion for Arcellx's next-generation CAR T candidate.
(2026) Clearing cholesterol combats secondary lymphoedema.
(2026) The pancreatic cancer drug market.
(2026) Unlocking the potential of disease prevention through regulatory science.
(2026) Accelerating the drug regulatory process through a federated cloud ecosystem.
(2026) Non-incretin approach for weight loss.
(2026) Upcoming FDA approval decisions in Q2 2026.
(2026) Digital endpoints in clinical trials: building the business case for systematic adoption.
(2026) Oral macrocyclic IL-23 inhibitor nabs FDA approval for psoriasis.
(2026) Exon skipping to treat Rett syndrome.
(2026) Enhancing CAR-NK cell efficacy in solid tumours.
(2026) Trikines rewire STAT signalling.
(2026) Targeted degradation of amyloid-β.
(2026) Wearable technologies in clinical trials for drug development: trends and emerging opportunities.
(2026)
